Abstract The chemotactic response of murine peritoneal macrophages to RANTES/CCL5 was inhibited significantly following pretreatment with delta-9-tetrahydrocannabinol (THC), the major psychoactive component in marijuana. Significant inhibition of this chemokine directed migratory response was obtained also when the full cannabinoid agonist CP55940 was used. The CB 2 receptor-selective ligand O-2137 exerted a robust inhibition of chemotaxis while the CB 1 receptor-selective ligand ACEA had a minimal effect. The THC-mediated inhibition was reversed by the CB 2 receptor-specific antagonist SR144528 but not by the CB 1 receptor-specific antagonist SR141716A. In addition, THC treatment had a minimal effect on the chemotactic response of peritoneal macrophages from CB 2 knockout mice. Collectively, these results suggest that cannabinoids act through the CB 2 receptor to transdeactivate migratory responsiveness to RANTES/CCL5. Furthermore, the results suggest that the CB 2 receptor may be a constituent element of a network of G protein-coupled receptor signal transductional systems, inclusive of chemokine receptors, that act coordinately to modulate macrophage migration.
Introduction
Delta-9-tetrahydrocannabinol (THC) is the major psychoactive component in marijuana. This exogenous cannabinoid exerts a variety of modulatory effects on the immune system, the majority of which have been reported to be immunosuppressive (Klein et al. 1998; Cabral and Dove Pettit 1998; Cabral and Staab 2005) . In this capacity, THC affects a diverse array of immune cell types, including B lymphocytes (Klein et al. 1985) , Natural Killer cells (Specter et al. 1986 ), T lymphocytes (Zimmerman et al. 1977) , macrophages (Raz and Goldman 1976; Friedman et al. 1986 ) and macrophage-like cells (Puffenbarger et al. 2000) . Cannabinoid effects on cellular systems can be by both receptor-mediated and nonreceptor-mediated modes (Makriyannis et al. 1990; Felder et al. 1992; Berdyshev et al. 2001; Price et al. 2004) . In terms of receptor-mediated action, two seven-transmembranal G i/o protein-coupled receptors have been linked to THC effects on immune function. The first of these, CB 1 , is found at highest levels in the central nervous system (Matsuda et al. 1990; Galiegue et al. 1995; Herkenham et al. 1991) and testis (Galiegue et al. 1995) but is present also at low levels in various immune cells (Galiegue et al. 1995; Daaka et al. 1996; Waksman et al. 1999) . The second receptor, CB 2 , is found primarily in immune cells (Munro et al. 1993; Galiegue et al. 1995) and appears to play a major role in immune modulation (Klein et al. 1998; Cabral and Dove Pettit 1998; Cabral and Staab 2005) .
Of the various immune cell populations affected by THC and other cannabinoids, macrophages and macrophage-like cells appear to be a major target (Munro et al. 1993; Cabral et al. 1995; Waksman et al. 1999; Puffenbarger et al. 2000) . Ultrastructural abnormalities have been observed in alveolar macrophages of humans who have been heavy users of marijuana (Mann et al. 1971 ) and in peritoneal macrophages of mice exposed in vitro to various concentrations of THC (Raz and Goldman 1976) . Various functional defects of alveolar and peritoneal macrophages from humans, rats, or mice following in vivo or in vitro exposure to marijuana or THC also have been reported. These alterations have included decreases in cell motility, ability to spread in vitro, release of β-glucuronidase, phagocytosis of yeast particles, and inactivation of Staphylococcus aureus and S. albus (Huber et al. 1975; Chari-Bitron 1976; McCarthy et al. 1976; Drath et al. 1979; Huber et al. 1978; Lopez-Cepero et al. 1986; Specter et al. 1991; Tang et al. 1992 ). In addition, THC has been reported to affect macrophage processing of soluble protein antigens (McCoy et al. 1995 (McCoy et al. , 1999 .
A critical activity of macrophages that is exerted early in the inflammatory process is the ability to migrate in response to stimuli. This migratory activity is distinctive from that of stimulus-independent random cellular motion (Lauffenburger and Horwitz 1996; Mitchison and Cramer 1996) . The two major modes of stimulus-dependent cellular motility are chemokinesis and chemotaxis. Chemokinesis is a process whereby cells exhibit random motion that is dependent on a chemo-stimulant (Becker 1977; Keller et al. 1978) . On the other hand, chemotaxis is a process in which cell motility is directed toward a concentration gradient of chemo-stimulant (Harris 1953 (Harris , 1954 Jin and Hereld 2006; Kehrl 2006) . In this chemotactic process, macrophage interaction with chemoattractants not only initiates a rapid and directed movement, but also is associated with a complex array of cellular events that includes changes in ion fluxes, alterations in integrin avidity, production of superoxide anions, and secretion of lysosomal enzymes (Murdoch and Finn 2000) . "Classical" chemoattractants include bacterial-derived N-formyl peptides, the complement fragment peptides C5a and C3a, and lipids such as leukotriene B 4 and platelet-activating factor (Schiffmann et al. 1975; Goldman and Goetzl 1982; Hanahan 1986; Gerard and Gerard 1994) . Chemokines represent a second group of chemoattractants. These 8-to 17-kD molecular mass range cytokines are selective for leukocytes in vitro and elicit accumulation of inflammatory cells in vivo (Baggiolini et al. 1994; 1997 , Kim 2004 Le et al. 2004) . Chemokines have been categorized into four groups on the basis of their cysteine motifs-CXC (α-chemokines), CC (β-chemokines), CX 3 X (δ-chemokines), and C (γ-chemokines; Murphy 2002) . As in the case for cannabinoid receptors, the specific effects of chemokines on target cells are mediated by G protein-coupled receptors (Murdoch and Finn 2000; Charo and Ransohoff 2006) . Ligation of chemokines with their cognate receptors initiates a series of signal transductional events that results in regulation of leukocyte trafficking in inflammation, tissue injury, tumor development and host response to infection (Charo and Ransohoff 2006) . Correlative to chemokine nomenclature, four families of chemokine receptors have been defined based on the chemokines they bind (Murphy 2002) .
In the present study, we demonstrate that THC inhibits the chemotactic response of murine peritoneal macrophages to RANTES/CCL5 [regulated upon activation normal T cell expressed and secreted/chemokine (C-C motif) ligand 5]. The inhibitory effect was shown to be linked functionally to the CB 2 , suggesting that cannabinoids can signal through this receptor to transdeactivate the chemokine receptormediated migratory response.
Materials and methods

Mice
Eight-week-old female (B 6 C 3 )F 1 and C57BL/6 mice were obtained from Taconic Laboratories (Hudson, NY). CB 2 (−/−) mice on a C57BL/6 background were obtained from Dr. Nancy E. Buckley (California Polytechnic University, Pomona, CA). CB 2 deficiency was confirmed by polymerase chain reaction (PCR) as described (Buckley et al. 2000; Chuchawankul et al. 2004 ). The animals were quarantined for 1 week before initiation of experiments and were used as a source of peritoneal macrophages. All the animal procedures were conducted in accordance with guidelines established by the Virginia Commonwealth University Institutional Animal Care and Use Committee (IACUC).
Cell culture
Thioglycollate-elicited peritoneal macrophages were obtained by injecting mice intraperitoneally with 1 ml 10% Brewer's yeast thioglycollate. Five days later, the cells were harvested and screened for purity for macrophages by FACScan analysis using monoclonal antibody for the murine macrophage marker F4/80 (Serotec, Kidlington, Oxford, UK). The cells that were greater than 95% positive for F4/80 were used in studies. Macrophages (10 7 /ml) in RPMI 1640 medium lacking serum and supplemented with 1% L-glutamine, 1% nonessential amino acids, 1% MEM vitamins, 0.01 M HEPES and penicillin (100 U/ml)/streptomycin (100 μg/ml)/fungizone (0.25 μg/ml) were used in chemotaxis assays.
Drugs
Delta-9-tetrahydrocannabinol (THC; Ki=40.7 nM), a partial agonist for CB 1 and CB 2 , was obtained from the National Institute on Drug Abuse (Rockville, MD). Additional cannabinoid analogs included the CB 1 and CB 2 full agonist CP55940 ((−)-cis-3-[2-Hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol; Ki=0.92 nM) and the highly selective CB 2 ligand O-2137-2 ((1R, 3R)-1-[4-(1,1-Dimethylheptyl)-2,6-dimethoxyphenyl]-3-methylcyclohexanol; CB 1 Ki=2700 nM, CB 2 Ki=11 nM). The highly selective CB 1 agonist ACEA (N-(2-Chloroethyl)-5Z,8Z,11Z,14Z-eicosatetraenamide; K i =1.4 nM) that displays >1,400-fold selectivity over CB 2 was purchased from Tocris Cookson (Ellisville, MO). The CB 1 and CB 2 antagonists SR141716 (5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(1-piperidyl)pyrazole-3-carboxamide hydrochloride; CB 1 Ki=2 nM, CB 2 Ki>1,000 nM) and SR144528 ((1S-endo)-5-(4-Chloro-3-methylphenyl)-1-((4-methylphenyl)methyl)-N-(1,3,3-trimethylbicyclo(2.2.1) hept-2-yl)-1H-pyrazole-3-carboxamide; CB 1 Ki=400 nM, CB 2 Ki=0.6 nM), respectively, were obtained from Sanofi Recherche (Montpellier, France). Stock solutions of cannabinoids (10 -2 M) were prepared in 100% ethanol and stored at −20°C. Experimental concentrations were obtained by dilution of cannabinoid stock solutions in RPMI 1640 medium used for macrophage culture to yield a final ethanol concentration of 0.01%. Vehicle controls consisted of 0.01% ethanol in medium.
Chemotaxis assay
Chemotaxis was measured using transwell inserts preloaded in 35-mm standard tissue culture plates (Corning, Corning, NY) , in which the upper and lower compartments were separated by a polycarbonate filter with 8 μm pores (Corning, Corning, NY). Peritoneal macrophages (1×10 7 /ml) were preincubated in RPMI 1640 lacking serum and containing vehicle (0.01% ethanol) or cannabinoid (10 -6 M-10 -12 M) for 3 h at 4°C. This time regimen for drug exposure was obtained through initial optimization experiments. Serum was omitted from the culture medium since it contains lipids and other factors that have the capacity to stimulate macrophage migration that could confound interpretation of migratory responses as attributable to RANTES. For experiments using antagonists, cells were exposed to SR141716A (10 -6 M) or SR144528 (10 -6 M) for 30 min before treatment with THC or CP55940 for 3 h. Following vehicle or cannabinoid treatment, 100 μl of drug-or vehicle-treated cell suspension (10 6 cells) were placed in the upper chamber of the transwell insert. For assessment of chemotaxis (directed migration against a chemokine concentration gradient) the lower compartment was loaded (600 μl) with medium containing murine RANTES (1 ng/ml; R&D Systems, Minneapolis, MN). This concentration of RANTES was selected based on preliminary titration for a chemoattractant response that approximated a midpoint in the linear phase of the dose-response curve. For assessment of chemokinesis (enhanced random migration to chemokine), RANTES (1 ng/ml) was included in both the top and bottom chambers to eliminate the chemoattractant concentration gradient. In addition, for a select number of experiments, RANTES was eliminated from both chambers. The assembled migration plate chamber system was incubated (1 h) at 37°C in a 5% CO 2 atmosphere. To determine the number of cells that migrated to the bottom chamber, the upper chamber (i.e., polycarbonate filter) was removed, and video still images (1 mm 2 ) in five random fields of each bottom chamber were captured using an Olympus CK2 inverted microscope (Opelco, Washington, DC) with an attached XV-GP230 digital video camera (Panasonic, Yokohama, Japan) interfaced to a Dell Dimension XPS1450 computer using Videum 100 hardware and Window NT software (Winnov, Sunnyvale, CA). The number of cells migrating into the bottom compartment/transwell plate was calculated as the sum of the five 1-mm 2 fields and was represented as cells/mm 2 /well. Each sample group was run in duplicate, and each experiment was performed in triplicate. Migration for each sample group was represented as the mean (±SD) of the total number of migrating cells counted in five fields of duplicate wells. A greater than twofold increase in cell migration to the chemoattractant RANTES in the lower compartment as compared to that in the absence of RANTES in the lower compartment was indicative of a positive response.
Reverse transcription-polymerase chain reaction (RT-PCR)
Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) using SYBR Green for CB 1 and CB 2 and GAPDH primers was used to assess for the presence of CB 1 and CB 2 mRNA. Total RNA from peritoneal macrophages was prepared using TRIzol reagent (Invitrogen, Carlsbad, CA) according the manufacturer's instructions. The RNA then was isolated by chloroform/isopropanol extraction and resuspended in 50-μl PCR grade water. The isolated RNA was treated with RNase-free DNase I Amplification grade (Invitrogen, Carlsbad, CA) to remove residual genomic DNA. The reverse transcription (RT) step was performed in a Bio-Rad iCycler (BioRad, Richmond, CA) using the SuperScript III First-Strand Synthesis System (Invitrogen) that included random hexamers as primer to generate complementary DNA (cDNA). SYBR Green real-time PCR was performed using the RT 2 PCR Primer Set for mouse CB 1 (Cnr 1: PPM04603A) or CB 2 (Cnr 2: PPM04826A) and GAPDH (GAPDH: PPM02946A) as described by the manufacturer (SuperArray Bioscience, Frederick, MD). Briefly, each 25 μl PCR mix consisted of 12.5 μl 2X RT 2 real-time SYBR Green PCR Master Mix (SuperArray), 2.0 μl first strand cDNA template, and 1.0 μl RT 2 PCR Primer Set brought to a final volume of 25 μl with DEPC-treated water. Tubes containing the PCR mix were placed in a SmartCycler (Cepheid, Sunnyvale, CA) and PCR was performed using the following program: 95°C, 15 min; 40 cycles of (95°C, 30 s; 55°C, 30 s; and 72°C, 30 s). The resulting PCR products were visualized by electrophoresis (100 V) using 4% OmniPur Agarose PCR Plus (VWR, West Chester, PA) gel in TBE. A pCD-SKR6 plasmid template (gift from Dr. L. Matsuda, Medical University of South Florida, Charleston, SC; Matsuda et al. 1990 ) and a pUC18-mCB 2 plasmid template (gift from T. Bonner, NIMH, Bethesda, MD) served as positive PCR controls for CB 1 and CB 2 , respectively. Using this approach, amplification products of 167 bp and 207 bp were generated for CB 1 and CB 2 , respectively.
Multiprobe ribonuclease protection assay
Total RNA prepared from peritoneal macrophages using TRIzol reagent (Invitrogen) was redissolved after isopropanol precipitation directly in 1X hybridization buffer (BD Biosciences/PharMingen, San Diego, CA). A Riboquant multiprobe ribonuclease protection assay (RPA) was used to assess for levels of murine chemokine receptor mRNA (mcr-5 probe template set; BD Biosciences/PharMingen). The ribo-probes were labeled with 32 P[UTP] (MP Biomedicals, Solon, OH) to a specific activity of greater than 3,000 Ci/mmol. The isolated RNA samples then were hybridized with the probe overnight at 56°C, and the protected fragments were resolved on a 6% polyacrylamide gel containing 6M urea. Imaging of the protected fragments was performed using a 445 SI Phosphorimager (Molecular Dynamics, Sunnyvale, CA). The pixel intensity of each band was quantified using ImageQuant 4.1 software (Molecular Dynamics), and the (B 6 C 3 )F 1 mice were injected intraperitoneally with 10% thioglycollate to elicit macrophages. Five days later, the mice were injected intraperitoneally with Vehicle (1:1:18, ethanol/emulphor/saline) or THC (25 or 50 mg/kg). Migration of macrophages to 1 ng/ml RANTES was assessed in vitro using transwell tissue culture inserts. Results are presented as the mean±SD. For RANTES placed only in the bottom chamber, SD was compared with that of vehicle-treated macrophages exposed to RANTES in the bottom chamber. For RANTES placed in both chambers (shaded bars), SD was compared with that of vehicle-treated macrophages exposed to RANTES in both chambers. When RANTES was added only to the bottom compartment, THC as compared to the vehicle control exerted a major inhibitory effect on cell migration to the bottom compartment. When RANTES was added to both the upper and lower compartments to eliminate the chemoattractant concentration gradient, THC as compared to the vehicle control did not result in significant inhibition of cell migration to the bottom well. These results indicate that THC inhibits directed migration (i.e., chemotaxis) to a RANTES concentration gradient rather enhancement of random movement (i.e., chemokinesis) to RANTES; asterisk, p<0.01 and double asterisk, p<0.001 amount of chemokine receptor mRNA was normalized for loading by dividing the pixel value for the chemokine receptor band by the sum of the pixel values for the mRNAs of the housekeeping genes, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and a ribosomal protein, L32.
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and western immunoblotting
Peritoneal macrophages suspended in sterile PBS were centrifuged (3,000×g, 10 min, 4°C) and the pellet was resuspended in an equal volume of sterile water containing a Protease Inhibitor Cocktail (100:1; Sigma, St. Louis, MO; 4-(2-aminoethyl) benzenesulfonyl fluoride, pepstatin A, E-64, bestatin, leupeptin, aprotinin). The cells then were subjected to three cycles of freeze-thaw and the lysate homogenized. Protein concentrations were determined by the Bradford assay (Bradford 1976) . Protein samples (40 μg/sample) were separated on a 12% polyacrylamide gel and transferred to a Transblot Transfer nitrocellulose membrane (BioRad, Hercules, CA). The membranes were incubated individually with anti-CCR1, anti-CCR5, and anti-CB 2 antibody. The antibody to CCR1 (CKR1 H-52, Santa Cruz Biotechnologies, CA) was directed against the extracellular amino terminus whereas the antibody to CCR5 (CKR5 D-19, Santa Cruz) was directed against the carboxy terminal domain. The antibody to CB 2 (M15 goat polyclonal antibody; Santa Cruz Biotechnologies) was raised against a peptide mapping to the C terminus of mouse CB 2 .
Statistical analysis
Analysis of variance (ANOVA) was performed using Dunnett's test and was followed by a Student's t test to allow for comparison of each sample to the vehicle. A Bonferroni t test was performed to assess differences between treatment groups.
Results
Murine thioglycollate-elicited peritoneal macrophages express the chemokine receptors CCR1 and CCR5 and the cannabinoid receptor CB 2 RANTES binds to the chemokine receptors CCR1, CCR3, and CCR5 (Murphy 2002; Bajetto et al. 2002; Charo and Ransohoff 2006) . Thus, to determine the CC chemokine receptor gene expression profile of (B 6 C 3 )F 1 and C57BL/6 murine thioglycollate-elicited peritoneal macrophages, a multiprobe RNase protection assay was employed. Using a template set for CC chemokine receptors, it was demonstrated that the predominant chemokine receptor mRNAs detected for (B 6 C 3 )F 1 mice were those for CCR1, CCR2, and CCR5 (Fig. 1a) . The C57BL/6 mice contained approximately equal levels of mRNA for CCR1 and CCR5 but, in contrast to (B 6 C 3 )F 1 mice, contained low levels of mRNA for CCR2. Because RANTES is a major agonist for CCR1 and CCR5, but not CCR2, the presence of protein for the former two receptors also was determined (Fig. 1d) . Consistent with the mRNA data, approximately equivalent levels of protein for CCR1 and CCR5 were detected in thioglycollateelicited macrophages of (B 6 C 3 )F 1 and C57BL/6 mice.
SYBR Green RT-PCR was employed to assess for the presence of CB 2 mRNA in peritoneal macrophages from (B 6 C 3 )F 1 and C57BL/6 mice. A 207 bp amplicon, consistent with the fragment size predicted for the CB 2 , was detected from total RNA of peritoneal macrophages (Fig. 1c) . Western immunoblot analysis using a murine CB 2 domainspecific antibody confirmed the presence of the CB 2 in murine peritoneal macrophages at the protein level (Fig. 1e) . CB 1 mRNA (Fig. 1b) or protein (data not shown) was not detected in thioglycollate-elicited peritoneal macrophages from (B 6 C 3 )F 1 and C57BL/6 mice.
Treatment with THC in vivo results in inhibition of the chemotactic response of murine peritoneal macrophages to RANTES in vitro The (B 6 C 3 )F 1 mice were inoculated with thioglycollate and 5 days later were administered a single intraperitoneal injection of vehicle (ethanol/emulphor/saline, 1:1:18) or THC (25 or 50 mg/kg). Peritoneal macrophages were harvested 24 h later and were subjected to migration assay. In vivo administration of 25 or 50 mg/kg THC resulted in a significant and greater than 50% inhibition of cell migration in response to RANTES as compared to that observed for cells of mice receiving vehicle (Fig. 2) . No significant differences in migration were obtained between vehicle and drug-treated cells when RANTES was placed in both the top and bottom compartments to eliminate the RANTES concentration gradient. These results are consistent with THC as exerting an inhibitory effect on the macrophage chemotactic response to RANTES.
Treatment with THC and CP55940 in vitro results in inhibition of the chemotactic response of murine peritoneal macrophages to RANTES To determine whether THC exerted a direct effect on macrophages, in vitro exposure experiments were performed. THC treatment of (B 6 C 3 )F 1 murine peritoneal macrophages in vitro resulted in a significant inhibition of the chemotactic response to RANTES (Fig. 3a) . Cells treated with vehicle exhibited a minimal level of migration (i.e., approximately 1,600 cells/mm 2 /well) to the bottom compartment in the absence of RANTES (Fig. 3a) . In contrast, when RANTES was added to the bottom compartment to establish a chemokine concentration gradient, a nearly fivefold increase (i.e., in excess of 5,000 cells/mm 2 /well) was obtained for macrophages treated with vehicle. Treatment of macrophages with THC (10 -6 M-10 -12 M) resulted in a significant inhibition of migration in response to RANTES. THC, at a concentration as low as 10 -12 M, exerted a major inhibitory effect on cell migration, with numbers of cells in the bottom compartment approximating those for cells treated with vehicle and not exposed to RANTES. Again, the inhibitory effect of THC on macrophage migration was at the level of chemotaxis rather than chemokinesis.
Experiments performed with THC were replicated using CP55940, a full agonist at CB 1 and CB 2 (Fig. 3b ). Again, a minimal level in cell migration was observed for control Results are presented as the mean±SD. For RANTES placed only in the bottom chamber, SD was compared with that of vehicle-treated macrophages exposed to RANTES in the bottom chamber. For RANTES placed in both chambers (shaded bars), SD was compared with that of vehicletreated macrophages exposed to RANTES in both chambers. Asterisk, p<0.05; double asterisk, p<0.01, triple asterisk, p<0.001
wells. Approximately 1,500 cells/mm 2 /well were recorded when vehicle-treated cells were placed in the top compartment in the absence of RANTES in the bottom compartment. An approximate fourfold increase in the number of peritoneal macrophages treated with vehicle was obtained when RANTES was placed in the bottom compartment to establish a chemoattractant gradient. Treatment of cells with CP55940 (10 -6 M-10 -12 M) resulted in a significant concentration-related decrease in migration in response to RANTES. A greater than 50% inhibition in migration was obtained for cells treated with CP55940 at 10 -6 M-10 -9 M as compared to vehicle control.
The CB 2 -selective ligand O-2137 exerts a robust inhibitory effect on the murine peritoneal macrophage chemotactic response to RANTES The concentration-related inhibitory effect on the chemotactic response of murine peritoneal macrophages to RANTES, most evident using CP55940, implicated a role for a cannabinoid receptor in this process. To obtain insight as to the cannabinoid receptor linked to the inhibitory effect, macrophages from (B 6 C 3 )F 1 mice were treated with compounds exhibiting selective high affinity binding to the CB 1 or the CB 2 antecedent to assessment of the chemotactic response. Treatment of macrophages with the highly selective CB 2 ligand O-2137 resulted in a profound and significant concentration-related inhibition in the chemotactic response to RANTES (Fig. 4a) . For drug concentrations of 10 -6 M-10 -8 M, a greater than 50% inhibition, as compared to vehicle control, was observed. Bonferroni t test analysis to assess differences in effect between O-2137 concentrations revealed significant differences in migration of cells treated with the drug at concentrations of 10 -6 M-10 -8 M when compared to 10 -11 M. In contrast, the CB 1 -selective ligand ACEA (10 -6 M-10 -12 M) exerted a minimal inhibitory effect on the peritoneal macrophage chemotactic response to RANTES (Fig. 4b 6 . Effect of THC on the chemotactic response of peritoneal macrophages from CB 2 knockout mice to RANTES. a in vitro THC treatment (3 h) did not have a significant effect on RANTES-induced migration by peritoneal macrophages from CB 2 receptor knockout mice. b THC treatment (3 h) resulted in a concentration-related inhibition of the chemotactic response of peritoneal macrophages to RANTES from the C57BL/6 CB 2 (+/+) wild-type counterpart.
Results are presented as the mean±SD. For RANTES placed only in the bottom chamber, SD was compared with that of vehicle-treated macrophages exposed to RANTES in the bottom chamber. For RANTES placed in both chambers (shaded bars), SD was compared with that of vehicle-treated macrophages exposed to RANTES in both chambers. Asterisk, p<0.05, double asterisk, p<0.01, triple asterisk, p<0.001
inhibition was obtained only for ACEA used at a concentration of 10 -7 M.
The CB 2 -specific antagonist SR144528 reverses the inhibitory effect of CP55940 on the murine peritoneal macrophage chemotactic response to RANTES To confirm the data indicating that activation of the CB 2 with a cannabinoid receptor selective ligand exerted a major inhibitory effect on the chemotactic response to RANTES, cannabinoid receptor agonist-antagonist experiments were performed. For these experiments, the CB 1 or CB 2 antagonist was used at a concentration of 10 -6 M. Treatment of (B 6 C 3 ) F 1 murine peritoneal macrophages with the CB 2 -specific antagonist SR144528 alone had no major effect on the chemotactic response to RANTES. At equimolar concentrations (i.e., 10 -6 M) of antagonist and agonist, CP55940 inhibited macrophage chemotaxis to RANTES. However, at lower concentrations (10 -7 M-10 -11 M) of CP55940, the inhibitory effect of the agonist was reversed by the CB 2 antagonist SR144528 (Fig. 5a ). These results were in contrast to those obtained when the CB 1 antagonist SR141716A was used (Fig. 5b) . SR141716A (10 -6 M-10 -12 M) did not block the inhibitory effect of CP55940. No significant difference was observed for RANTES-induced migration of peritoneal macrophages treated with 10 -6 M CP55940 versus that of peritoneal macrophages treated with equimolar (i.e., 10 -6 M) concentrations of CP55940 and SR141716A.
THC does not inhibit the chemotactic response to RANTES of peritoneal macrophages from CB 2 knockout mice To confirm the pharmacological data implicative of a functional linkage of the CB 2 to cannabinoid-mediated inhibition of macrophage chemotaxis to RANTES, experiments were performed using thioglycollate-elicited peritoneal macrophages from C57BL/6 CB 2 knockout mice. THC (10 -5 M-10 -9 M) had no significant effect on either the chemotactic or chemokinetic response of macrophages from the knockout mice (Fig. 6a) . Since these CB 2 null animals were generated on a C57BL/6 genetic background, replicate migration experiments were performed using thioglycollate-elicited peritoneal macrophages from their C57BL/6 CB 2 (+/+) wild-type counterparts. THC exerted a concentration-related inhibition of the chemotactic response of peritoneal macrophages to RANTES (Fig. 6b) .
THC does not alter mRNA levels of CC chemokine receptors in thioglycollate-elicited murine peritoneal macrophages Chemotaxis to RANTES results from a complex series of signal transductional activities after ligation of the chemokine to its cognate G protein-coupled receptor. THC treatment of macrophages could affect activation of chemokine receptors and alter their expression and/or compartmentalization. Thus, to obtain initial insight as to the mode of action through which THC treatment results in inhibition of chemotaxis, experiments were performed to assess for levels CC chemokine receptor mRNA in peritoneal macrophages. THC (10 -6 M-10 -12 M) treatment (3 h) had no major effect on total mRNA levels of CCR1, CCR2 or CCR5 (Fig. 7) . In addition, chemokine receptor mRNA levels were assessed in peritoneal macrophages exposed to THC in vivo (50 mg/kg THC for 24 h before harvest from mice). Consistent with results obtained in vitro, THC treatment had no major effect on the expression of CCR1, CCR2, or CCR5 at the level of total mRNA (Data not shown). Similarly, at this concentration range THC had no major effect on total mRNA levels of CB 2 (Data not shown).
Discussion
THC, the major psychoactive component in marijuana, has been shown to alter the activities of macrophages and macrophage-like cells, including phagocytosis Lopez-Cepero et al. 1986; Tang et al. 1992; Ehrhart et al. 2005) , antigen processing (McCoy et al. 1995 (McCoy et al. , 1999 , and production of chemokines and cytokines (Watzl et al. 1991; Zheng et al. 1992; Puffenbarger et al. 2000) . Recent studies indicate that this exogenous canna- Multiprobe ribonuclease protection assay demonstrated that THC (10 −6 M-10 −12 M) treatment (3 h) had no major effect on levels of CCR1, CCR2, and CCR5 mRNA in thioglycollate-elicited (B 6 C 3 )F 1 murine peritoneal macrophages binoid, as well as other cannabinoids, also affects the migratory activities of macrophages. Stefano et al. (1998) reported that acute exposure to the endogenous cannabinoid (endocannabinoid) anandamide resulted in transformation of macrophages from an amoeboid and motile state to that of a rounded and nonmotile conformation. These investigators proposed that the transforming events were linked to the CB 1 since the CB 1 -specific antagonist SR141716A blocked the transformation. Sacerdote et al. (2000) demonstrated that in vivo and in vitro treatment of rat peritoneal macrophages with CP55940, a full agonist at both CB 1 and CB 2 , resulted in decreased migration in vitro to the peptide formyl-methionyl-leucinephenylalanine (fMLP). It was indicated that, while both the CB 1 and CB 2 receptors appeared to be involved in this process, the cannabinoid-mediated effect was linked primarily to the CB 2 . The chemotactic response of murine macrophages to fMLP also has been shown to be decreased by cannabidiol (Sacerdote et al. 2005) , a cannabinoid that binds weakly to CB 2 . The CB 2 antagonist SR144528 prevented this decrease, suggesting a functional linkage to this receptor. On the other hand, Walter et al. (2003) found that the endocannabinoid 2-arachidonylglycerol (2-AG) triggered migration of microglia, macrophages that are resident in the brain, and that the CB 2 was involved in this effect. Additionally, these investigators and others (Jordá et al. 2002; Kishimoto et al. 2005 ) demonstrated that THC did not induce a migratory cellular response in natural killer cells or cells of myeloid origin and, further, inhibited migration of these cell types to 2-AG. Collectively, these studies suggest that exogenous cannabinoids exert inhibitory effects on macrophage migration while endocannabinoids elicit an opposite effect.
Consistent with these observations, in the present study, we demonstrate that THC inhibits the chemotactic or directed migratory response of murine peritoneal macrophages to RANTES, a chemokine that can signal through the chemokine receptors CCR1 and CCR5. This effect was exerted on peritoneal macrophages from mice administered THC or on peritoneal macrophages that were exposed directly to THC in vitro. In the latter context, the inhibition occurred over a wide concentration range (i.e., 10 -6 M-10 -12 M). These results are consistent with THC as having a direct effect on macrophages, which results in inhibition of chemotaxis. The results obtained with THC were replicated using the full CB 1 /CB 2 agonist CP55940. Treatment of murine macrophages in vitro with CP55940 resulted in inhibition of chemotaxis to RANTES over the same concentration range (i.e., 10 -6 M-10 -12 M) of THC. To establish whether the cannabinoid-mediated inhibition was linked to a cannabinoid receptor, a series of experiments was performed in which cannabinoid receptor-selective ligands as well as cannabinoid receptor-specific antagonists were used. Treatment of macrophages in vitro with O-2137, a compound that exhibits high selectivity for the CB 2 , resulted in a robust inhibition of macrophage chemotaxis. In contrast, the CB 1 -selective compound ACEA had a minimal effect. In addition, the CB 2 antagonist SR144528 blocked CP55940-mediated inhibition of macrophage chemotaxis while the CB 1 antagonist SR141716A had a minimal effect. Finally, THC was not able to inhibit the chemotactic response to RANTES of peritoneal macrophages obtained from CB 2 knockout mice. Collectively, the results of experiments in which a pharmacological approach was complemented with that using macrophages from CB 2 null (i.e., CB 2 −/−) mice support the proposition that the CB 2 is linked functionally to the cannabinoid-mediated inhibition of chemotaxis to RANTES.
RANTES, for which the current International Union of Pharmacology nomenclature is CCL5 (Murphy 2002) , is one of many chemotactic cytokines that direct the migration of leukocytes to sites of infection and inflammation. In this capacity, these small molecular weight proteins constitute a critical component of innate immune defenses. Four subfamilies of chemokines have been identified based on the relative position of their Nterminal cysteine residues. All chemokines bind specific receptors that are seven-transmembranal and are coupled to heterotrimeric G i proteins, a feature that is shared with cannabinoid agonists. However, binding within a chemokine subfamily is somewhat promiscuous. In the present study, we examined thioglycollate-elicited peritoneal macrophages from (B 6 C 3 )F 1 and C57BL/6 mice for their CC chemokine receptor expression profile. These cells were shown to express CCR1 and CCR5, receptors that can bind RANTES. Thus, in the context of our experimental paradigm, it is possible that RANTES acted through one or both receptors to induce chemotactic activity. In turn, THC may have affected the functionality of one or both chemokine receptors. Regardless of which of the chemokine receptors found on macrophages is functionally relevant in RANTES-mediated signaling, the results of this study suggest that cannabinoid activation of the CB 2 can result in deactivation of other members of the G protein-coupled family such as chemokine receptors. Studies utilizing chemokine receptor-specific antagonists should serve to identify the CC receptor type that is linked to RANTES-mediated chemotactic activity that is targeted by cannabinoids.
The mode by which THC and other cannabinoid analogs signal through cannabinoid receptors to deactivate CCR1 and/or CCR5 chemokine receptor migratory responsiveness to RANTES remains to be defined. THC and other cannabinoids, as highly lipophilic molecules, can perturb cellular membranes (Martin 1986; Makriyannis et al. 1990; Cabral and Staab 2005) . Such perturbation could alter conformational strictures requisite for ligand-receptor interaction, disrupt receptor-G protein complexes, and disturb intracellular membranous compartments that are linked to biochemical events in the cascade of signal transduction. However, as suggested by the present study, cannabinoids also may transdeactivate chemokine receptors and affect their ability to elicit a signal transductional cascade that culminates in the chemotactic migratory response. Indeed, it has been reported that members of the G protein-coupled receptor superfamily can associate with each other, forming homodimers and heterodimers that results in alteration in the functionality of one of the involved receptors (Rios et al. 2001) . Opioid receptors, for example, have been reported to interact with chemokine receptors to alter their function. Grimm et al. (1998) indicated that this interaction resulted in trans-deactivation of chemokine receptors and that it occurred through a process of receptor-mediated heterologous desensitization. In their studies, Met-enkephalin and morphine were shown to inhibit interleukin (IL)-8-induced chemotaxis of human neutrophils and macrophage inflammatory protein (MIP)-1α, RANTES, and monocyte chemoattractant protein (MCP)-1-mediated chemotaxis of human monocytes. This inhibition was mediated by δ and μ opioid receptors, the activation of which led to phosphorylation of the chemokine receptors CXCR1 and CXCR2 resulting in heterologous desensitization. Rogers et al. (2000) reported that activation of opioid and chemokine receptors could lead to reciprocal down-regulation of leukocyte migratory activities. These observations have been extended using a number of experimental paradigms Szabo et al. , 2002 Suzuki et al. 2002; Zhang et al. 2003) . Indeed, it has been proposed that crossdesensitization of chemokine receptors by opioids represents a significant element in opioid-mediated immunosuppression (Zhang et al. 2003) . The process of heterologous desensitization may also apply to cannabinoid receptors. Ghosh et al (2006) reported that the CB 1 /CB 2 agonist CP55940, as well as the CB 2 -selective agonist JW-015, caused significant inhibition of chemokine CXCL12-induced chemotaxis of CD4+ and CD8+ T lymphocytes. These investigators also found that these cannabinoids inhibited CXCL12 induced chemotaxis and transendothelial migration of Jurkat T cells. Rios et al. (2006) reported recently that the μ opioid receptor also interacts with the CB 1 to effect a reciprocal inhibition of receptor signaling and neuritogenesis.
In the present study, the pharmacological data suggested that heterologous desensitization constituted a mode of action by which cannabinoids mediate inhibition of the murine peritoneal macrophage chemotactic response to RANTES. Thus, to obtain initial insight as to the process by which THC and other cannabinoids cross-deactivate this macrophage activity, a multiprobe RNase protection assay was performed to assess for levels of CC chemokine receptor mRNAs. THC over a concentration range of 10 -6 M to 10 -12 M had no observable effect on macrophage mRNA levels of CCR1 and CCR5. These results are consistent with THC-mediated inhibition of the chemotactic process as occurring at a site upstream to gene expression of the cognate receptors at the mRNA level. Studies are in progress to assess for effects of THC on protein expression and phosphorylation of CCR1, CCR5, and CB 2 in the context of the chemotactic response.
In summary, we have demonstrated that THC and cannabinoids that activate the CB 2 inhibit murine peritoneal macrophage chemotaxis to RANTES/CCL5. This inhibitory effect was linked functionally to the CB 2 . Furthermore, since this chemokine serves as a ligand for CCR1 and CCR5, these results suggest that activation of the CB 2 leads to transdeactivation of these G protein-coupled receptors of the CC chemokine subfamily that have specialized roles in leukocyte trafficking. Thus, as has been suggested for opioid receptors, CB 2 "cross-talk" with chemokine receptors, may constitute an integrative component of a network of intercommunicating G protein-coupled receptors that regulate immune responses.
